Protalix BioTherapeutics (PLX) Accumulated Expenses (2011 - 2026)

Protalix BioTherapeutics has reported Accumulated Expenses for 12 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 175.33% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 175.33% YoY), and the FY2025 full-year result was $799000.0, down 55.88% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.7 million, up from $799000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $9.0 million in Q4 2023, with the low at $763000.0 in Q2 2025.
• Average Accumulated Expenses over 4 years is $3.7 million, with a median of $1.8 million recorded in 2024.
• Year-over-year, Accumulated Expenses sank 79.9% in 2024 and jumped 175.33% in 2026.
• Tracing PLX's Accumulated Expenses over 4 years: stood at $9.0 million in 2023, then slumped by 79.9% to $1.8 million in 2024, then tumbled by 55.88% to $799000.0 in 2025, then surged by 363.83% to $3.7 million in 2026.
• The last three Accumulated Expenses figures came in at $3.7 million (Q1 2026), $799000.0 (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.

Peer Comparison